Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal meningitis
- Focus Pharmacodynamics
- Sponsors sanofi pasteur
- 28 Jun 2017 Planned End Date changed from 1 May 2018 to 11 Oct 2017.
- 28 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 11 Oct 2017.
- 13 Apr 2017 Status changed from recruiting to active, no longer recruiting.